

DAFTAR PUSTAKA

1. Eslam M, Sarin SK, Wong VWS, et al. *The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease*. Vol 14. Springer India; 2020. doi:10.1007/s12072-020-10094-2
2. Pipitone RM, Ciccioli C, Infantino G, et al. MAFLD: a multisystem disease Rosaria. *Ther Adv Endocrinol Metab.* 2023;14:1-23. doi:10.1177/20420188221145549
3. Gofton C, Upendran Y, Zheng M, George J. MAFLD : How is it different from NAFLD ? 2023;29.
4. Hasan I. Perlemakan Hati Non Alkoholik. In: *Buku Ajar Ilmu Penyakit Dalam. Edisi VI*. interna Publishing Pusat penerbitan Ilmu Penyakit Dalam; 2014:2000-2005.
5. Abdelmalek MF, Anna Mae Diehl. Nonalcoholic Fatty Liver Diseases and Nonalcoholic Steatohepatitis. In: *Harrison's Principles of Internal Medicine. 21th Ed*. McGraw-Hill Education; 2022:2619-2624.
6. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology.* 2023;77(4):1335-1347. doi:10.1097/hep.0000000000000004
7. García-Compeán D, Jiménez-Rodríguez AR. NAFLD VS MAFLD. The evidence-based debate has come. Time to change? *Ann Hepatol.* 2022;27(6):20-23. doi:10.1016/j.aohep.2022.100765
8. Wang S, Friedman SL. Found in Translation – Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis (MASH). 2023;15(716). doi:10.1126/scitranslmed.adi0759.Found
9. Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases : a clinical review. *Clin Res Cardiol.* 2021;110(7):921-937. doi:10.1007/s00392-

020-01709-7

10. Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease : From Steatosis to Cirrhosis Introduction : Early Insights and. 2005;(1998):99-112. doi:10.1002/hep.20973
11. Heyens LJM, Busschots D, Koek GH, Robaey G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. *Front Med.* 2021;8(April):1-20. doi:10.3389/fmed.2021.615978
12. Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: From pathogenesis to clinical impact. *Processes.* 2021;9(1):1-18. doi:10.3390/pr9010135
13. Bachhav G, Locheruvapalli Venkateshappa L, Avinash B, Patil M, Bonthala Subbara S, Ravikiran SK. Comparison of Transient Elastography and Liver Biopsy in Assessing Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. *J Ren Hepatic Disord.* 2021;5(1):38-43. doi:10.15586/jrenhep.v5i1.90
14. Tovo C V., Villela-Nogueira CA, Leite NC, et al. Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). *Ann Hepatol.* 2019;18(3):445-449. doi:10.1016/j.aohep.2018.09.003
15. Adams LA, Anstee QM, Tilg H, Targher G. Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut.* 2017;66(6):1138-1153. doi:10.1136/gutjnl-2017-313884
16. Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. *Atherosclerosis.* 2019;282(July 2018):110-120. doi:10.1016/j.atherosclerosis.2019.01.029
17. Bocatonda A, Andreetto L, Ardes DD, et al. From NAFLD to MAFLD : Definition , Pathophysiological Basis and Cardiovascular Implications. 2023;11(3):1-15. doi:10.3390/biomedicines11030883
18. Arslan U, Yenerçağ M. Relationship between non-alcoholic fatty liver disease

and coronary heart disease. *World J Clin Cases*. 2020;8(20):4688-4699. doi:10.12998/wjcc.v8.i20.4688

19. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology*. 2015;61(5):1547-1554. doi:10.1002/hep.27368
20. Tomeno W, Imajo K, Takayanagi T, et al. Complications of non-alcoholic fatty liver disease in extrahepatic organs. *Diagnostics*. 2020;10(11):1-12. doi:10.3390/diagnostics10110912
21. Gholoobi A, Gifani M, Gholoobi A, Akhlaghi S, Pezeshki Rad M, Baradaran Rahimi V. Relationship between the prevalence and severity of non-alcoholic fatty liver disease and coronary artery disease: Findings from a cross-sectional study of a referral center in northeast Iran. *JGH Open*. 2022;6(5):330-337. doi:10.1002/jgh3.12746
22. Alon L, Corica B, Raparelli V, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2022;29(6):938-946. doi:10.1093/eurjpc/zwab212
23. Yan Z, Liu Y, Li W, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis. *Eur J Clin Invest*. 2022;52(11):1-18. doi:10.1111/eci.13855
24. Jamalnia M, Zare F, Lankarani KB. Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2023;58(4):384-394. doi:10.1111/apt.17617
25. Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. *Hepatol Int*. 2023;17(4):773-791. doi:10.1007/s12072-023-10543-8
26. Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. *Gut Liver*. 2021;15(2):206-216. doi:10.5009/GNL20127
27. Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN.

Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. *Front Med.* 2024;11(January). doi:10.3389/fmed.2024.1291501

28. Fu Y, Wang Z, Qin H. Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective. *Metabolites.* 2024;14(4). doi:10.3390/metabo14040218
29. Binet Q, Loumaye A, Preumont V, Thissen J, Hermans MP, Lanthier N. Non-invasive screening , staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ? 2022;85(June):346-357. doi:10.51821/85.2.9775
30. Marchesini G, Day CP, Dufour J-F, Canbay A, Nobili V, Ratziu V. Clinical Practice Guidelines EASL – EASD – EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease q. *J Hepatol.* 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004
31. Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non - invasive diagnosis and staging of non - alcoholic fatty liver disease. *Hormones.* Published online 2022:349-368. doi:10.1007/s42000-022-00377-8
32. Segura-azuara ND, Varela-chinchilla CD, Trinidad-Calderon P. MAFLD / NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. 2022;8(January):1-11. doi:10.3389/fmed.2021.774079
33. Lekakis V, Papatheodoridis G V. Natural history of metabolic dysfunction-associated steatotic liver disease. *Eur J Intern Med.* 2024;122(October 2023):3-10. doi:10.1016/j.ejim.2023.11.005
34. Ag MT, Erkan H. Association Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease Complexity in Patients With Acute Coronary Syndrome : A Pilot Study. 2013;64(8):604-608. doi:10.1177/0003319713479155
35. Loscalzo J. Approach to the Patient with Possible Cardiovascular Disease. In: *Harrison's Principles of Internal Medicine.* 21st ed. McGraw-Hill Education;

2022:1797.

36. Arso IA, Ambari AM, Hartopo AB, Al E. *Panduan Prevensi Penyakit Kardiovaskuler Aterosklerosis*. edisi pert. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Jakarta; 2022.
37. Olvera L, Ballard B, Jan A. Cardiovascular Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Published 2023. Accessed September 1, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK535419/>
38. Rusmona AP. pencegahan dan penatalaksanaan aterosklerosis. In: *Buku Ajar Ilmu Penyakit Dalam Edisi VI*. Interna Publishing; 2014:1425-1435.
39. Neumann FJ, Sechtem U, Banning AP, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
40. Nakashima M, Nakamura K, Nishihara T, Ichikawa K, Nakayama R. Association between Cardiovascular Disease and Liver Disease ., Published online 2023.
41. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced Fibrosis is Associated with Incident Cardiovascular Disease in Patients with Non-Alcoholic Fatty Liver Disease. *Aliment Pharmacol Ther*. 2020;51(7):728–736. doi:10.1111/apt.15660
42. Shroff H, VanWagner LB. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. *Curr Hepatol Reports*. 2020;19(3):315-326. doi:10.1007/s11901-020-00530-0
43. Badmus OO, Hinds TD, Stec DE. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease. *Curr Hypertens Rep*. 2023;25(8):151-162. doi:10.1007/s11906-023-01242-8
44. Man S, Deng Y, Ma Y, et al. Prevalence of Liver Steatosis and Fibrosis in the General. *Gastroenterology*. 2023;165(4):1025-1040. doi:10.1053/j.gastro.2023.05.053
45. Baratta F, Pastori D, Angelico F, et al. Nonalcoholic Fatty Liver Disease and

- Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. *Clin Gastroenterol Hepatol*. 2020;18(10):2324-2331.e4. doi:10.1016/j.cgh.2019.12.026
46. Tamaki N, Kurosaki M, Takahashi Y, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. *J Gastroenterol Hepatol*. 2021;36(10):2960-2966. doi:10.1111/jgh.15589
 47. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2015;149(2):389-397.e10. doi:10.1053/j.gastro.2015.04.043
 48. Study TM, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population. Published online 2018:1-10. doi:10.1161/CIRCIMAGING.117.007241
 49. Cardoso CRL, Villela-Nogueira CA, Leite NC, Salles GF. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. *Cardiovasc Diabetol*. 2021;20(1):1-11. doi:10.1186/s12933-021-01388-2
 50. Dang HNN, Luong TV, Tran TT, Hoang TA. The correlation between liver fibrosis and the 10-year estimated risk of cardiovascular disease in adults with metabolic-associated fatty liver disease: A cross-sectional study in Vietnam. *Heal Sci Reports*. 2024;7(5). doi:10.1002/hsr2.2102
 51. VanWagner LB, Wilcox JE, Ning H, et al. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. *J Am Heart Assoc*. 2020;9(4). doi:10.1161/JAHA.119.014279
 52. Simon T, Bamira D, Chung R, Weiner R, Corey K. Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction. *Obes (Silver Spring)*. 2017;25(8):1313–1316. doi:10.1002/oby.21879.

53. Johnson PC, Cochet AA, Gore RS, et al. Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver Disease. *Korean J Gastroenterol.* 2021;78(3):161-167. doi:10.4166/kjg.2021.040
54. Goland S, Shimoni S, Zornitzki T, et al. Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment. *J Clin Gastroenterol.* 2006;40(10):949-955. doi:10.1097/01.mcg.0000225668.53673.e6
55. Ismaiel A, Popa S, Dumitrascu DL. Acute Coronary Syndromes and Nonalcoholic Fatty Liver Disease : “ Un Affaire de Coeur .” 2020;2020.
56. Montemezzo M, Alturki A, Stahlschmidt F, Olandoski M, Rodrigo Tafarel J, Precoma DB. Nonalcoholic Fatty Liver Disease and Coronary Artery Disease: Big Brothers in Patients with Acute Coronary Syndrome. *Sci World J.* 2020;2020. doi:10.1155/2020/8489238
57. Ghoneim S, Dhorepatil A, Shah AR, et al. Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. *World J Hepatol.* 2020;12(7):378-388. doi:10.4254/wjh.v12.i7.378
58. Whitsett M, Wilcox J, Yang A, Zhao L, Rinella M, VanWagner LB. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. *Liver Int.* 2019;39(5):933-940. doi:10.1111/liv.14018
59. Zhou B, Ju SY, Mei YZ, et al. A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation. *Front Endocrinol (Lausanne).* 2023;14(July):1-13. doi:10.3389/fendo.2023.1160532
60. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. *Cardiovasc Diabetol.* 2024;23(1). doi:10.1186/s12933-024-02434-5